Ogden syndrome

Ogden syndrome (also known as N-alpha-acetyltransferase 10 deficiency or NAA10-related syndrome) is an extremely rare X-linked genetic disorder caused by pathogenic variants in the NAA10 gene, which encodes the catalytic subunit of the N-terminal acetyltransferase A (NatA) complex. This enzyme is responsible for N-alpha-acetylation of proteins, a critical post-translational modification affecting protein stability and function. The condition was first described in a family from Ogden, Utah, and primarily affects males, who are more severely impacted than females. Ogden syndrome is characterized by a severe multisystem presentation beginning in the neonatal or early infantile period. Key clinical features include global developmental delay, intellectual disability, postnatal growth failure, distinctive craniofacial features (such as large fontanelles, prominent eyes, and aged appearance), cardiac anomalies (including arrhythmias and hypertrophic cardiomyopathy), and hypotonia. Affected males may also exhibit cryptorchidism, sensorineural hearing loss, and skeletal abnormalities. The condition is often associated with significant morbidity and early mortality in males, with many affected boys dying in infancy or early childhood due to cardiac complications or other organ failure. There is currently no cure or disease-specific treatment for Ogden syndrome. Management is supportive and multidisciplinary, focusing on addressing individual symptoms such as cardiac monitoring and intervention, nutritional support, physical and occupational therapy, and developmental services. Genetic counseling is recommended for affected families. Research into the molecular mechanisms of NatA complex dysfunction is ongoing, but no targeted therapies are yet available.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Ogden syndrome